Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 -1.07%74 Debt-to-Equity is 0.08 as of Mar. 2026, which is 33% above its 10-year median of 0.06. GuruFocus rates TPE:6598 with a GF Score™ of 74/100 and a GF Value™ of NT$27.80 (Fairly Valued). The stock has 6 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Applied BioCode ranks better than 72.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Applied BioCode's Debt-to-Equity or its related term are showing as below:
TPE:6598'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.72
Current: 0.08
During the past 13 years, the highest Debt-to-Equity Ratio of Applied BioCode was 0.72. The lowest was 0.01. And the median was 0.06.
TPE:6598's Debt-to-Equity is ranked better than 72.82% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs TPE:6598: 0.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Applied BioCode Debt-to-Equity Related Terms
Applied BioCode Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Applied BioCode's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied BioCode (TPE:6598) has a Debt-to-Equity of 0.08 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Applied BioCode and its competitors. This is 33% above median its historical median of 0.06. Over the past decade, Applied BioCode's Debt-to-Equity has ranged from 0.01 to 0.72. According to the industry distribution chart, Applied BioCode ranks #190 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 27.2%.
Is Applied BioCode's Debt-to-Equity too high?
Applied BioCode's current Debt-to-Equity of 0.08 is 33% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.72. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Applied BioCode's value of 0.08 is 65.2% below this industry median. Based on the distribution chart, Applied BioCode ranks #190 out of 699 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #190 out of 699 companies for Debt-to-Equity. This puts Applied BioCode in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Applied BioCode's value of 0.08 is 65.2% below this benchmark. Historically, Applied BioCode's own Debt-to-Equity has ranged from 0.01 to 0.72 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.23, Applied BioCode has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current Debt-to-Equity of 0.08 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Debt-to-Equity is 0.08, which is 33% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$27.80, compared to a current price of NT$27.70 — trading 0.4% below its estimated fair value. The current Debt-to-Equity is 0.08, which is 33% above median its 10-year median of 0.06 and 65.2% below the Medical Devices & Instruments industry median of 0.23. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Debt-to-Equity is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$27.70 is trading 0.4% below its estimated GF Value™ of NT$27.80.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Debt-to-Equity: 0.08 (33% above median its 10-year median of 0.06)
GF Value™: NT$27.80 vs. price of NT$27.70 (0.4% below fair value)
Industry Position: 65.2% below the Medical Devices & Instruments median (#190 of 699)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
